If you ever met CANCER you must know how tough it is, tough to fight with it, tough to watch how your beloved struggle and sometimes the only thing that can help is chemo 😬
But chemo also not easy to go through, thats why you need to know about G1 Therapeutics and Cosela! 🎁
Investing in a start-up biotech company is an absolute roller coaster -clinical trials can both bring highs and lows but not in G1 Therapeutics case, beacuse it's key drug COSELA™ (trilaciclib) has been approved by FDA at 02.12.2021. Simple profit taking has snowballed into a huge sell-off, with the stock dropping more than 40%.So, COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy. Myeloprotective efficacy of COSELA resulted in reductions in the incidence and duration of severe neutropenia, and impacted anemia and the need for rescue interventions such as growth factors and red blood cell transfusions. Myelosuppression is the most serious and life-threatening side effect of chemotherapy, or damage to the bone marrow, resulting in reduced white blood cells, red blood cells and platelets. Chemotherapy-induced myelosuppression may lead to increased risks of infection, severe anemia, and/or bleeding. These complications impact patients’ quality of life and may also result in chemotherapy dose reductions and delays. To date, approaches have included the use of growth factor agents to accelerate blood cell recovery after the bone marrow injury has occurred, along with antibiotics and transfusions as needed.
💊By contrast, trilaciclib provides the first proactive approach to myelosuppression through a unique mechanism of action that helps protect the bone marrow from damage by chemotherapy. In the... keep reading on reddit ➡
I’m not sure if this is shrinkflation, or I’m rocking above average tea holding vessels.
- G1’s COSELA™ (trilaciclib), the Only FDA-Approved Proactive Multilineage Myeloprotection Therapy, Approved on February 12, 2021 and Commercially Available as of March 2, 2021 -
- Strong Total Revenue of $14.2 Million Included $0.6 Million from Initial Sales of COSELA in First Four Weeks of Product Availability -
- COSELA Added to Two National Comprehensive Cancer Network® (NCCN) Guidelines Which Inform Reimbursement and Formulary Decisions -
- Pivotal Phase 3 Trial of COSELA in Metastatic Triple-Negative Breast Cancer Underway to Evaluate the Survival Benefit of COSELA Compared with Placebo -
- As of March 31, 2021, cash and cash equivalents totaled $279.0 million, compared to $207.3 million as of December 31, 2020. This includes $86.4 million in net proceeds in the first quarter from the “At the Market” offering with Cowen and Company, LLC. This ATM offering is now closed. In addition, the Company drew the additional $10M available in the first tranche of debt on its debt financing facility with Hercules Capital. The Company has access to an additional $70 million through this facility.
This is just the beginning of our journey